Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Merrill

Showing results (251-260 of 414) with videos related to

Pageof 42
Sort By:
Arthritis and Rheumatism|August 29, 2009
Novel evidence-based systemic lupus erythematosus responder indexRichard A Furie, Michelle A Petri, Daniel J Wallace, et al.
Ophthalmology|October 4, 2016
Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)Quan Dong Nguyen, Pauline T Merrill, W Lloyd Clark, et al.
Arthritis and Rheumatism|June 8, 2012
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosusJoan T Merrill, Ellen M Ginzler, Daniel J Wallace, et al.
Arthritis and Rheumatism|December 30, 2009
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialJoan T Merrill, C Michael Neuwelt, Daniel J Wallace, et al.
Arthritis Research & Therapy|March 20, 2020
Low frequency of flares during pregnancy and post-partum in stable lupus patientsJulia Davis-Porada, Mimi Y Kim, Marta M Guerra, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
Rheumatology International|June 24, 2009
Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular diseaseAllison B Reiss, Kamran Anwar, Joan T Merrill, et al.
Arthritis and Rheumatism|May 21, 2011
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic featuresSherry R Crowe, Joan T Merrill, Evan S Vista, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Lupus Science & Medicine|February 3, 2016
Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study resultsCecile M Yelnik, Carl A Laskin, T Flint Porter, et al.
Pageof 42

Showing results (251-260 of 414) with videos related to

Sort By:
Pageof 42
Arthritis and Rheumatism|August 29, 2009
Novel evidence-based systemic lupus erythematosus responder indexRichard A Furie, Michelle A Petri, Daniel J Wallace, et al.
Ophthalmology|October 4, 2016
Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)Quan Dong Nguyen, Pauline T Merrill, W Lloyd Clark, et al.
Arthritis and Rheumatism|June 8, 2012
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosusJoan T Merrill, Ellen M Ginzler, Daniel J Wallace, et al.
Arthritis and Rheumatism|December 30, 2009
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialJoan T Merrill, C Michael Neuwelt, Daniel J Wallace, et al.
Arthritis Research & Therapy|March 20, 2020
Low frequency of flares during pregnancy and post-partum in stable lupus patientsJulia Davis-Porada, Mimi Y Kim, Marta M Guerra, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
Rheumatology International|June 24, 2009
Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular diseaseAllison B Reiss, Kamran Anwar, Joan T Merrill, et al.
Arthritis and Rheumatism|May 21, 2011
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic featuresSherry R Crowe, Joan T Merrill, Evan S Vista, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Lupus Science & Medicine|February 3, 2016
Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study resultsCecile M Yelnik, Carl A Laskin, T Flint Porter, et al.
Pageof 42